1. Home
  2. STTK vs CAAS Comparison

STTK vs CAAS Comparison

Compare STTK & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.05

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

CAAS

China Automotive Systems Inc.

HOLD

Current Price

$4.37

Market Cap

123.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
CAAS
Founded
2016
N/A
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
123.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
CAAS
Price
$3.05
$4.37
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
392.9K
24.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.68
EPS
N/A
1.11
Revenue
$1,000,000.00
$725,260,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.89
Revenue Growth
N/A
16.72
52 Week Low
$0.69
$3.50
52 Week High
$3.38
$5.37

Technical Indicators

Market Signals
Indicator
STTK
CAAS
Relative Strength Index (RSI) 67.21 55.85
Support Level $2.82 $4.06
Resistance Level $3.30 $4.43
Average True Range (ATR) 0.24 0.15
MACD -0.00 0.03
Stochastic Oscillator 74.76 71.11

Price Performance

Historical Comparison
STTK
CAAS

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About CAAS China Automotive Systems Inc.

China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.

Share on Social Networks: